Cough And Cold Symptoms, Some Coming From Omicron, Sound Like Seasonal Rebound To Perrigo
Consumer Health Product Firm Notes Potential Sales Impact From Russia’s Invasion Of Ukraine
Sales growth generated in October-December period and growing incidences of flu and cough/cold symptoms are harbingers for Perrigo in 2022. Sales during January and February in Russia and Ukraine tracked with $10m to $15m operating income firm anticipates there for 2022, “but it's really too early to estimate the potential full-year impact,” CEO Murray Kessler says.
You may also be interested in...
With Raymond Silcock’s work at Perrigo linked to CEO Murray Kessler’s time with the firm and with the two working together previously as CFO and CEO at a tobacco firm, whether Kessler continues at the helm could become a topic of shareholder interest.
Paris-based HRA Pharma reported significant sales gains for its key consumer health brands in 2021, helping to lift group turnover by more than 25%. This is likely to be the last set of results posted by HRA as a standalone company with Perrigo optimistic its proposed acquisition of the firm will soon complete.
GSK will spin-off its consumer health business in July under the name Haleon. The standalone operation expects to outpace market growth rates by expanding in emerging markets, tapping into consumer demand for more natural products and delivering two Rx-to-OTC switches in the US.